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Abstract:  The tumor promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulates cell migration of several 
tumor cells. Recently, we reported that loss of lysophosphatidic acid (LPA) receptor-3 (LPA3) enhanced cell migration of 
murine lung tumor LL/2 cells. In the present study, we investigated whether LPA3 is involved in cell migration of mouse 
lung tumor cells stimulated by TPA. Exogenous LPA3 gene (Lpar3)-expressing (LL/2-a3) cells and LL/2-AB cells as a 
vector control generated from LL/2 cells were used. In a cell migration assay, TPA treatment significantly stimulated cell 
migration of LL/2-AB and LL/2-a3 cells, while the cell migration abilities of LL/2-a3 were markedly lower than those 
of LL/2-AB cells. Using quantitative real-time reverse transcription (RT)-polymerase chain reaction (PCR) analysis, 
no effect of TPA treatment on the expression levels of LPA1, LPA2 and LPA3 genes was detected in either type of cells. 
These results suggest that the LPA3 may not be involved in the enhanced migration ability by TPA in mouse lung tumor 
cells. (DOI: 10.1293/tox.24.183; J Toxicol Pathol 2011; 24: 183–186)
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Lysophosphatidic acid (LPA) is a bioactive mediator 
and interacts with at least six G protein-coupled transmem-
brane receptors, LPA receptor-1 (LPA1), LPA2, LPA3, LPA4, 
LPA5 and LPA6
1–4. After binding to LPA receptors (LPARs), 
LPA induces several biological effects, such as cell prolif-
eration, differentiation, morphogenesis and protection from 
apoptosis1–4. In cancer cells, LPA can also enhance cell 
growth, migration, invasion and tumorigenicity1,5,6.
Previously, aberrant expressions of LPAR genes have 
been detected in human malignancies, including ovary, co-
lon and thyroid tumors7–11. Recently, we have also reported 
that the distinct expression patterns of LPAR genes due to 
DNA methylation were found in human and mouse tumor 
cells12,13. Therefore, this suggests that the biological func-
tions of LPARs may be dependent on the type of cancer 
cells. In fact, LPA3 enhanced cell migration and invasion of 
human ovarian cancer cells14. By contrast, we have reported 
that LPA3 inhibited cell migration abilities of murine lung 
tumor cells15.
It is well known that 12-O-tetradecanoylphorbol-
13-acetate (TPA) is a tumor promoting agent that inhibits 
gap junctional intercellular communication in various cells 
types16,17. TPA also enhances cell migration through acti-
vation of protein kinase C (PKC) in some tumor cells18,19. 
In the present study, to clarify an involvement of LPA sig-
naling pathway in TPA-stimulated cell migration of tumor 
cells, we investigated cell migration of mouse lung tumor 
cells treated with TPA and measured the expression levels 
of LPAR genes in those cells. We used the two cell lines, ex-
ogenous LPA3 gene (Lpar3)-expressing (LL/2-a3) cells and 
LL/2-AB (vector) cells. LL/2-a3 cells showed significantly 
lower cell migration ability than control LL/2-AB cells15.
LL/2-a3 cells were generated from mouse LL/2 lung 
tumor cells using retroviruses coexpressing green fluores-
cent protein (GFP) from an internal ribosomal entry site as 
described previously15. LL/2-AB cells were also used as a 
control clone. All cells were cultured in DMEM containing 
10% fetal bovine serum in a 5% CO2 atmosphere at 37 °C.
For the cell migration assay, an uncoated Cell Culture 
Insert (BD Falcon, Franklin Lakes, NJ, USA) with an 8-μm 
pore size was used. Cells were pretreated with TPA (5 nM) 
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(Wako Pure Chemical Industries, Ltd., Osaka, Japan) for 
48 h and seeded into the filter at 1 × 105 cells in 200 µl of 
serum-free DMEM (upper chamber) and placed in 24-well 
plates (lower chamber) containing 800 µl of 5% charcoal 
stripped FBS (Sigma Biochemicals, St. Louis, MO, USA) 
–DMEM with or without LPA (10 μM) (Avanti Polar Lipids, 
Inc., Alabaster, AL, USA). After incubation for 24 h, cells 
remaining in the upper side of the filter were removed with 
cotton swabs. The percentage of cells migrated to the lower 
side of the filter was counted after Giemsa staining. Each 
experiment was repeated three times15.
Total RNA was extracted from each cell using ISO-
GEN (Nippon Gene Co., Ltd., Toyama, Japan), and first-
strand cDNA was synthesized with Transcriptor First 
Strand cDNA Synthesis Kit (Roche Diagnostics GmbH, 
Mannheim, Germany). To assess the expression patterns 
the Lpar1, Lpar2 and Lpar3 genes in TPA-treated cells, re-
verse transcription (RT)-polymerase chain reaction (PCR) 
analysis was performed15. The amplified PCR products were 
separated on 2% agarose gels containing 0.05 µg/ml ethid-
ium bromide. The expression levels of those genes were also 
measured by quantitative real-time RT-PCR analysis using a 
SYBR Premix Ex Taq (TaKaRa Bio, Inc., Shiga, Japan) and 
a SmartCycler II System (TaKaRa)13. The rat Gapdh gene 
was used as an internal control gene. The data of the target 
genes were normalized to Gapdh. Each assay was repeated 
at least twice for confirmation.
The morphological appearances of the LL/2-AB and 
LL/2-a3 cells used in this study are shown in Fig. 1. The cell 
growth rate between the two types of cell indicated the same 
levels in DMEM containing 10% FBS (data not shown).
To assess cell migration of LL/2-AB and LL/2-a3 cells 
stimulated by TPA, the cells were treated with TPA for 48 h. 
While LL/2-a3 cells showed lower cell migration than LL/2-
AB cells, the cell migration abilities of LL/2-AB and LL/2-
a3  cells  were  significantly  stimulated  by  TPA  treatment 
(Fig. 2A). Furthermore, to evaluate the effect of LPA on 
cell migration stimulated by TPA, LPA was added into the 
lower chamber of the Cell Culture Insert and TPA-treated 
cells were incubated for 24 h. LPA treatment significantly 
increased the cell migration of both types of cells treated 
with TPA (Fig. 2B).
The LPAR gene expressions in LL/2-AB and LL/2-a3 
cells treated with TPA were measured by semiquantitative 
RT-PCR and quantitative real-time RT-PCR analyses. No 
effect of TPA treatment on the expression levels of Lpar1, 
Lpar2 and Lpar3 was detected in either type of cells (Fig. 
3A, B).
LPA3 acts as a positive or negative regulator of cell mi-
gration, depending on the cell type. In human ovarian can-
cer cells, exogenous LPAR1, LPAR2 or LPAR3-expressing 
cells acquired high malignant potency, and transfection of 
small interfering RNAs suppressed cell migration and in-
vasion of those cells14. By contrast, the exogenous Lpar3-
expressing LL/2-a3 cells showed lower cell migration than 
control LL/2-AB cells15.
TPA has several biological effects, including the in-
hibition of gap junctional intercellular communication and 
stimulation of cell migration through activation of PKC in 
various cell types16–19. Thus, to clarify the involvement of 
LPA3 in cell migration of mouse lung tumor cells treated 
with TPA, we investigated cell migration of LL/2-a3 and 
LL/2-AB cells treated with TPA, and measured the expres-
sion levels of LPA receptor genes in those cells. The results 
indicated that TPA stimulated the cell migration abilities of 
both LL/2-a3 and LL/2-AB cells, but did not affect the ex-
pression levels of their LPAR genes, suggesting that LPA3 
may not be involved in cell migration of mouse lung tumor 
cells stimulated by TPA.
A previous report showed that LPARs may form het-
erodimers with other receptors, resulting in novel signaling 
and different functional behaviors20. Therefore, the involve-
Fig. 1. Morphology of LL/2-AB (vector) and LL/2-a3 (Lpar3-ex-
pressing) cells in serum-containing medium.Okumura, Kato, Fukui et al. 185
Fig. 2.  The cell migration assay. Columns indicate the means of three studies; bars indicate SD. (A) 
Cell migration of LL/2-AB and LL/2-a3 cells stimulated by TPA. Cells were treated with or 
without TPA for 48 h. (B) Effects of LPA on TPA-stimulated cell migration of LL/2-AB and 
LL/2-a3 cells. TPA-treated cells were incubated for 24 h with or without LPA (10 μM). Cells 
incubated without LPA were used as the control.
Fig. 3.  (A) Expression patterns of LPAR gene mRNAs by semiquantitative RT-PCR analysis. (B) Relative expression levels 
of LPAR gene mRNAs relative to Gapdh mRNA by quantitative real-time RT-PCR analysis. LL/2-AB and LL/2-a3 
cells were treated with TPA for 48 h.Cell Migration of Mouse Lung Tumor by TPA 186
ment of other LPARs in cell migration of tumor cells treated 
with TPA should be further studied.
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